EMG
TENX icon

Ellington Management Group’s Tenax Therapeutics TENX Stock Holding History

Ellington Management Group’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1
Closed -$154K – 764
2013
Q4 		$154K Buy
+1
New +$135K 0.05% 501

Other funds holding TENX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ellington Management Group's TENX Position: Q1 2014 in Review

Ellington Management Group sold out of Tenax Therapeutics (TENX) in Q1 2014, closing a stake of 1 share — an estimated $154K sold.

Ellington Management Group first reported a position in TENX in Q4 2013 and held it in 1 quarter. The position peaked at $154K in Q4 2013. 16 funds tracked by Wall St. Rank hold TENX as of Q1 2014.

  • Ellington Management Group reported no remaining Tenax Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Ellington Management Group sold 1 Tenax Therapeutics share in Q1 2014, an estimated $154K.
  • Ellington Management Group first reported a position in Tenax Therapeutics in Q4 2013 and held it in 1 quarter.
  • Ellington Management Group's Tenax Therapeutics position peaked at $154K in Q4 2013.
  • 16 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2014.

Based on Ellington Management Group's 13F filing for Q1 2014, filed 15 May 2014.